Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.
| Autor: | Sasso, Bruna Lo, Gambino, Caterina Maria, Scichilone, Nicola, Giglio, Rosaria Vincenza, Bivona, Giulia, Scazzone, Concetta, Muratore, Roberto, Milano, Salvatore, Barbagallo, Mario, Agnello, Luisa, Ciaccio, Marcello |
|---|---|
| Předmět: |
BIOMARKERS
REVERSE transcriptase polymerase chain reaction STATISTICS COVID-19 SCIENTIFIC observation CONFIDENCE intervals RETROSPECTIVE studies ARTIFICIAL respiration HOSPITAL mortality DESCRIPTIVE statistics PEPTIDE hormones POLYMERASE chain reaction RECEIVER operating characteristic curves ODDS ratio DATA analysis DATA analysis software |
| Zdroj: | Laboratory Medicine; Sep2021, Vol. 52 Issue 5, p493-498, 6p |
| Abstrakt: | Objective The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. Methods We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Results Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3–2.95 vs median, 0.82 nmol/L; interquartile range, 0.57–1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001). Conclusion We found that MR-proADM could represent a prognostic biomarker of COVID-19. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|